BioIntervene, Inc. is a preclinical-phase pharmaceutical company dedicated to discovering and creating effective and non-habit-forming medications for long-lasting discomfort and other long-lasting inflammatory and neurodegenerative ailments. The organization was established in 2014 utilizing insights from research at Saint Louis University and the National Institutes of Health (NIH). BioIntervene’s original team has pioneered the comprehension of adenosine A3 receptor biology, concentrating on developing innovative, discerning adenosine A3 receptor agonists.
BioIntervene
Headquarters
United States of America